MX351104B - Nuevos glucosaminoglucanos con baja actividad anticoagulante. - Google Patents

Nuevos glucosaminoglucanos con baja actividad anticoagulante.

Info

Publication number
MX351104B
MX351104B MX2014007122A MX2014007122A MX351104B MX 351104 B MX351104 B MX 351104B MX 2014007122 A MX2014007122 A MX 2014007122A MX 2014007122 A MX2014007122 A MX 2014007122A MX 351104 B MX351104 B MX 351104B
Authority
MX
Mexico
Prior art keywords
coagulative
glycosaminoglycans
medical use
disaccharide unit
repeating disaccharide
Prior art date
Application number
MX2014007122A
Other languages
English (en)
Other versions
MX2014007122A (es
Inventor
Hans-Peter Ekre
Ulf Lindahl
Erik Holmer
Per-Olov Eriksson
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX351104(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of MX2014007122A publication Critical patent/MX2014007122A/es
Publication of MX351104B publication Critical patent/MX351104B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un glucosaminoglucano químicamente modificado con una actividad antifactor II de menos de 10 UI/mg, una actividad antifactor Xa de menos de 10 UI/mg y un peso molecular promedio (promedio en peso, Mw) de desde aproximadamente 4,6 hasta 6,9 kDa. También se divulga un procedimiento de preparación del glucosaminoglucano modificado y sus usos médicos.
MX2014007122A 2011-12-19 2012-12-19 Nuevos glucosaminoglucanos con baja actividad anticoagulante. MX351104B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (2)

Publication Number Publication Date
MX2014007122A MX2014007122A (es) 2015-03-05
MX351104B true MX351104B (es) 2017-10-02

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007122A MX351104B (es) 2011-12-19 2012-12-19 Nuevos glucosaminoglucanos con baja actividad anticoagulante.

Country Status (28)

Country Link
US (1) US9475888B2 (es)
EP (1) EP2794665B1 (es)
JP (2) JP6543467B2 (es)
KR (1) KR102135485B1 (es)
CN (1) CN104144950B (es)
AU (1) AU2012354229B2 (es)
BR (1) BR112014014454B1 (es)
CA (1) CA2856492C (es)
CL (1) CL2014001651A1 (es)
CO (1) CO7061069A2 (es)
CY (1) CY1119899T1 (es)
DK (1) DK2794665T3 (es)
ES (1) ES2656613T3 (es)
HK (1) HK1202883A1 (es)
HR (1) HRP20180124T1 (es)
HU (1) HUE036523T2 (es)
IL (1) IL232905A (es)
LT (1) LT2794665T (es)
ME (1) ME02994B (es)
MX (1) MX351104B (es)
NO (1) NO2904345T3 (es)
PL (1) PL2794665T3 (es)
PT (1) PT2794665T (es)
RS (1) RS56874B1 (es)
RU (1) RU2617764C2 (es)
SI (1) SI2794665T1 (es)
WO (1) WO2013095279A1 (es)
ZA (1) ZA201403640B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
MX2014011451A (es) * 2012-03-26 2014-11-10 Dilafor Ab Procedimiento de tratamiento de la interrupcion del parto.
RU2014143017A (ru) * 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
AU2013260209A1 (en) * 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
BR112016025443A2 (pt) * 2014-04-30 2017-12-12 Agency Science Tech & Res sulfatos de heparano
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
AU2021223494A1 (en) 2020-02-17 2022-08-04 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
AR129190A1 (es) 2022-05-03 2024-07-31 Dilafor Ab Nuevo uso médico de la tafoxiparina

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
JP4203611B2 (ja) 1996-10-15 2009-01-07 生化学工業株式会社 子宮頸管熟化剤
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
WO2000006608A1 (fr) * 1998-07-31 2000-02-10 Seikagaku Corporation Nouveau glycosaminoglycan et compositions medicamenteuses le contenant
CA2341668A1 (en) * 1998-08-26 2000-03-09 The Collaborative Group, Ltd. Receptor for underivatized, aqueous soluble beta-(1,3)-glucan
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
JP4911865B2 (ja) * 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
WO2007014155A2 (en) 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
AU2006272780A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compostions and selectin inhibition
EP3495822B1 (en) * 2006-04-04 2023-12-20 Novilux, LLC Method for assessing acute myocardial infarction based on highly sensitive analysis of cardiac troponin
EP2019843A2 (en) * 2006-05-25 2009-02-04 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
AU2008318343B2 (en) * 2007-11-02 2013-07-18 Dilafor Ab Non-anticoagulant polysaccharide compositions
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
BRPI0909849A2 (pt) 2008-04-04 2015-10-06 Univ Utah Res Found éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los
EP2411448B1 (en) * 2009-03-27 2013-03-20 Actamax Surgical Materials LLC Polyglycerol aldehydes
EP2419736B1 (en) 2009-04-16 2014-01-29 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
KR20120060209A (ko) * 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
EP2515957B1 (en) * 2009-12-22 2015-07-29 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2014143017A (ru) 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
MX2014011451A (es) 2012-03-26 2014-11-10 Dilafor Ab Procedimiento de tratamiento de la interrupcion del parto.

Also Published As

Publication number Publication date
CN104144950A (zh) 2014-11-12
RS56874B1 (sr) 2018-04-30
RU2617764C2 (ru) 2017-04-26
EP2794665A1 (en) 2014-10-29
LT2794665T (lt) 2017-12-27
US9475888B2 (en) 2016-10-25
NO2904345T3 (es) 2018-07-21
HRP20180124T1 (hr) 2018-02-23
PL2794665T3 (pl) 2018-04-30
KR20140113652A (ko) 2014-09-24
RU2014129816A (ru) 2016-02-20
BR112014014454A2 (pt) 2017-06-13
PT2794665T (pt) 2018-01-24
CY1119899T1 (el) 2018-06-27
DK2794665T3 (da) 2018-01-29
HUE036523T2 (hu) 2018-07-30
CN104144950B (zh) 2017-09-05
ZA201403640B (en) 2017-06-28
CA2856492A1 (en) 2013-06-27
IL232905A (en) 2017-02-28
AU2012354229A1 (en) 2014-06-05
JP6543467B2 (ja) 2019-07-10
AU2012354229B2 (en) 2016-12-01
SI2794665T1 (en) 2018-03-30
US20150011505A1 (en) 2015-01-08
CO7061069A2 (es) 2014-09-19
CA2856492C (en) 2017-01-10
MX2014007122A (es) 2015-03-05
BR112014014454B1 (pt) 2021-03-09
HK1202883A1 (en) 2015-10-09
WO2013095279A1 (en) 2013-06-27
ES2656613T3 (es) 2018-02-27
ME02994B (me) 2018-10-20
JP2015500388A (ja) 2015-01-05
CL2014001651A1 (es) 2014-10-10
EP2794665B1 (en) 2017-11-22
EP2794665A4 (en) 2015-08-26
KR102135485B1 (ko) 2020-07-17
IL232905A0 (en) 2014-07-31
JP2018111825A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2014007122A (es) Nuevos glucosaminoglucanos con baja actividad anticoagulante.
IN2014MN01056A (es)
MX363923B (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
TN2010000086A1 (en) Antiviral composition comprising a sulfated polysaccharide
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
LT2429515T (lt) Nauji vaistai, skirti vietiniam naudojimui sulfatuotos hialurono rūgšties, kaip citokinų aktyvumą aktyvuojančio arba inhibuojančio agento, pagrindu
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
WO2018056937A3 (en) Nanofibrous adhesion barrier
PH12014502680A1 (en) Polysaccharide compositions and methods of use
NZ603479A (en) Chitosan composition
MX2012007166A (es) Composicion antiviral sinergica y su uso.
NZ595969A (en) Use of galacto-oligosaccharide in the prevention of an inflammatory disorder
MX2019009711A (es) Mejoras en o con respecto a compuestos organicos.
JP2007126453A5 (es)
WO2013160349A3 (en) Cosmetic composition comprising a phosphorylated oligosaccharide and a polysaccharide
IN2015DN02358A (es)
TR201908669T4 (tr) N-desülfatlanmış glikozaminoglikanların türevleri ve ilaç olarak kullanımı.
RU2016116786A (ru) Иммуностимулятор
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
BR112013009185A2 (pt) uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.
MX2015013122A (es) Composiciones hidrofílicas de hialuronato modificado, revestimientos y métodos.
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
WO2011155800A3 (ko) 히알루론산의 탈아세틸화 가수분해효소, 및 이에 의해 탈아세틸화된 히알루론산 및 이의 유도체
MX2012006966A (es) Tratamiento de padecimientos mediados por citocina.

Legal Events

Date Code Title Description
FG Grant or registration